v2.4.0.6
Other Consolidated Financial Statement Detail (Details) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Other Income (Expense), Net          
Interest income $ 5,900,000 $ 5,300,000 $ 22,600,000 $ 13,300,000  
Interest expense (8,700,000) (7,900,000) (23,100,000) (25,500,000)  
Impairment of investments (3,500,000) (800,000) (4,800,000) (7,600,000)  
Gain (loss) on sales of investments, net 1,300,000 (100,000) 15,600,000 15,400,000  
Foreign exchange gains (losses), net 100,000 (4,800,000) 200,000 (5,800,000)  
Other, net 400,000 600,000 3,100,000 700,000  
Total other income (expense), net (4,548,000) (7,727,000) 13,546,000 (9,504,000)  
Accrued Expenses and Other          
Employee compensation and benefits 198,700,000   198,700,000   176,300,000
Revenue-related rebates 160,200,000   160,200,000   115,000,000
Deferred revenue 140,600,000   140,600,000   69,600,000
Collaboration expenses 46,600,000   46,600,000   44,200,000
Clinical development expenses 52,900,000   52,900,000   40,800,000
Royalties and licensing fees 45,300,000   45,300,000   47,400,000
Current portion of contingent consideration obligations 21,300,000   21,300,000   10,800,000
Other 200,600,000   200,600,000   173,100,000
Total accrued expenses and other $ 866,208,000   $ 866,208,000   $ 677,210,000